Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
Terminated · Phase 2 · NCT04659603
Conditions: Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic
At a glance
- Research payments reported, 2025
- $25,730
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 50
About the trial
- Sponsor
- Sanofi
- Tested
- tusamitamab ravtansine (drug), Gemcitabine (drug)
- Dates
- Started 2021-03-29; completion 2025-01-19
- Results posted
- Yes
Primary Objective: * For Cohort A, Cohort B, and Cohort C Part 2: To assess the antitumor activity of tusamitamab ravtansine in metastatic breast cancer (mBC) and tusamitamab ravtansine monotherapy and in combination with gemcitabine in metastatic pancreatic adenocarcinoma (mPAC) * For Cohort C Part 1: Confirmation of the recommended tusamitamab ravtansine dose when administered in combination with gemcitabine Secondary Objectives: * To assess the safety and tolerability of tusamitamab ravtansine administered as monotherapy and in combination with gemcitabine * To assess other efficacy parameters of tusamitamab ravtansine administered as monotherapy and in combination with gemcitabine * T…
From ClinicalTrials.gov, last updated 2025-10-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $25,730 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Board of Regents of the University of Wisconsin System $25,730
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.